RARE vs RGNX Stock Comparison

Compare RARE and RGNX across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.

Market data as of Sep 11, 2026 market close· AIQ score gap 0 points
RARE
Healthcare
vs
RGNX
Healthcare
RARE
Ultragenyx Pharmaceutical Inc.
Price
$14.30
Day move
-0.69%
AIQ Score
43/100
Best edge
Quality
Sector
Healthcare
RGNX
REGENXBIO Inc.
Price
$8.53
Day move
-0.35%
AIQ Score
43/100
Best edge
Risk Resilience
Sector
Healthcare

What is the main difference between RARE and RGNX?

RARE and RGNX are close on the current AIQ evidence, so the better fit depends more on objective, risk tolerance and valuation preference than on a single headline score.

AlgovestIQ AIQ Comparison

Ultragenyx Pharmaceutical Inc. vs REGENXBIO Inc.

Data as of Sep 11, 2026· market close· Healthcare· Coverage 66/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 2/10

RARE and RGNX are effectively level

RARE and RGNX are effectively level on the AIQ Score; the factor table below shows where each one holds its advantage.

Evidence agreement: 2 of 6Comparison trend: Stable
RARE

Ultragenyx Pharmaceutical Inc.

AIQ Score
43/100
AIQ Edge Score
3/10
RGNX

REGENXBIO Inc.

AIQ Score
43/100
AIQ Edge Score
3/10

The Algovestiq AIQ Score does not currently separate RARE and RGNX as of Sep 11, 2026. Both names are scored on the same 0–100 scale across Quality, Value, Momentum and Risk Resilience, and the factor table below shows where each one holds its advantage.

Compare Ultragenyx Pharmaceutical Inc. and REGENXBIO Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price-return comparison using available daily close history.

RARE
-85.7%
RGNX
-80.3%

Total return comparison

Growth of $10,000

RARE $1,433 · RGNX $1,972

Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.

Compare RARE and RGNX against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

RARE advantage
0
RGNX advantage
  • Risk Resilience21 vs 55
    RGNX +34
  • Quality64 vs 40
    RARE +24
  • Value50 vs 56
    RGNX +6
  • Momentum21 vs 25
    RGNX +4

Neither name separates cleanly on the covered dimensions.

What changed since the last close

Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.

RARE0 AIQ

No factor moved materially.

New signals

  • 52-Week Low Proximity bearish, risk, long horizon (1.0%)
RGNX0 AIQ

No factor moved materially.

No new signals fired.

Deeper signal detail for each name lives on its own signals page — RARE and RGNX both carry a full feed there.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

Even

Neither separates on the overall score.

Growth

RGNX

RGNX on combined revenue and EPS growth.

Value

RGNX

RGNX on the peer-relative Value factor, by 6 points.

Momentum

RGNX

RGNX on the Momentum factor, by 4 points.

Lower downside

RGNX

RGNX on Risk Resilience, by 34 points.

Analyst upside

Even

Analyst targets are level or not covered for both names.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureRARERGNXNote
Implied upside to target+154.9%+154%Level
Target dispersion+183.8%+92.3%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering125Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

How each independent group of evidence reads the pair.

Evidence groupFavorsReading
AIQ ScoreEven43 vs 43
FundamentalsRAREon balancerevenue growth 57.4% vs 15.9%; EPS growth 51.1% vs 125%; TTM ROE 3.9% vs -220.1%; gross margin 83.1% vs 54.2%; operating margin -73.8% vs -94.1% — RARE takes 4 of 5 decided legs, not all of them
ValuationRGNXValue 50 vs 56
TechnicalsRGNXPrice vs 50-day -46.4% vs -20.9%; vs 200-day -44% vs -16.8%
Risk ResilienceRGNXRisk Resilience 21 vs 55
Analyst expectationsEvenTarget upside 154.9% vs 154%

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is narrow at 0 points. (argues the conclusion is provisional)
  • Only 2 of 6 covered evidence groups agree. (argues the conclusion is provisional)
  • Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)

How the comparison changed

119 daily snapshots · May 4 Sep 10

RGNX lead: Stable — the AIQ differential has held near 0 points over 30 sessions.

May 4RARE leads above the line · RGNX leads belowSep 10
Today
Level
43 vs 43
7 sessions ago
RGNX +1
43 vs 44
30 sessions ago
RGNX +1
49 vs 50
90 sessions ago
RARE +8
58 vs 50

The lead changed hands 4 times in this window, most recently on Sep 3 when RGNX moved ahead of RARE.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

RAREConflicted

2 bullish / 3 bearish / 1 neutral, conflicted

  • Golden Cross Active bullish, trend, long horizon (3.69%)
  • Keltner Channel Breakdown bearish, volatility, short horizon
  • RSI Oversold - Potential Bounce bullish, momentum, short horizon
RGNXConflicted

1 bullish / 1 bearish / 2 neutral, conflicted

  • Golden Cross Active bullish, trend, long horizon (4.81%)
  • Bollinger Band Squeeze neutral, volatility, short horizon
  • ATR Expansion - Breakout Mode neutral, volatility, short horizon (8.07%)

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

RARENo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.69%, AIQ 0 points).

RGNXNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.35%, AIQ 0 points).

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

RARE leads on balance
MetricRARERGNX
Revenue growth (YoY)57.4%15.9%
EPS growth (YoY)51.1%125%
Gross margin83.1%54.2%
Operating margin-73.8%-94.1%
Return on equity (TTM)3.9%-220.1%
Debt to equity-4.130.96

Performance

RGNX leads 5 of 6 windows
MetricRARERGNX
1 week (5 sessions)-41.1%-10.8%
1 month (20 sessions)-43.4%-21.5%
3 months (63 sessions)-37.3%39.6%
6 months (126 sessions)-35.2%-8.7%
Year to date-37.4%-40.6%
1 year (252 sessions)-54.3%-9.7%

Technicals

RGNX has the stronger structure
MetricRARERGNX
RSI (14)18.130.1
ADX (14)27.215.3
Price vs 50-day-46.4%-20.9%
Price vs 200-day-44%-16.8%
Volatility (1M, annualized)159.7%114.3%

Risk

RGNX is the more resilient
MetricRARERGNX
Beta1.191.98
Sharpe ratio-0.520.3
Sortino ratio-0.50.36
Max drawdown-60.8%-64.6%
Current drawdown-60.6%-46.4%
Annualized volatility80.5%93.4%
Value at risk (95%)-4.3%-8.2%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which has more analyst upside, RARE or RGNX?

Analyst price targets imply +154.9% upside for RARE and +154% for RGNX. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, RARE or RGNX?

RGNX is the better-valued of the two on the peer-relative Value factor. RGNX on the peer-relative Value factor, by 6 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, RARE or RGNX?

RGNX on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, RARE or RGNX?

RGNX on the Momentum factor, by 4 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, RARE or RGNX?

RGNX is the more resilient of the two, so the other name carries the higher downside risk. RGNX on Risk Resilience, by 34 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is RARE more profitable than RGNX?

RARE leads on the comparable margin measures — gross margin 83.1% vs 54.2%; operating margin -73.8% vs -94.1%; ttm roe 3.9% vs -220.1%.

What do the current signals say about RARE and RGNX?

RARE: 2 bullish / 3 bearish / 1 neutral, conflicted. RGNX: 1 bullish / 1 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on RARE is Golden Cross Active (bullish, long horizon). On RGNX it is Golden Cross Active (bullish, long horizon).

Compare RARE and RGNX with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.